Name | CPI-637 |
Description | CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor. |
Cell Research | AMO-1 cells (DSMZ) were plated at 20,000 cells/well in 96-well plates in Iscove's Modified Dulbecco's Medium supplemented with 10% fetal calf serum. Cells were treated for 6 h with a dose titration of CPI-637 starting from a 5 μM top concentration. After 6 h, cells were lysed and processed for QuantiGene Plex expression analysis and data were collected on a MAGPIX multiplex Luminex instrument.(Only for Reference) |
Kinase Assay | Ki Determination: Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis. |
In vitro | CPI-637 inhibits MYC expression in AMO-1 cells (EC50=0.60 μM)[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 3.87 mg/mL (10 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble)
|
Keywords | Inhibitor | inhibit | HAT | Epigenetic Reader Domain | Histone Acetyltransferase | HATs | CPI637 | CPI-637 |
Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | Acetaminophen | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin |
Related Compound Libraries | Highly Selective Inhibitor Library | Histone Modification Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |